Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. Furst DE, et al. Among authors: keystone e. Rheumatology (Oxford). 2013 Oct;52(10):1845-55. doi: 10.1093/rheumatology/ket233. Epub 2013 Jul 9. Rheumatology (Oxford). 2013. PMID: 23838027 Free PMC article.
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Kay J, et al. Among authors: keystone e. Ann Rheum Dis. 2015 Mar;74(3):538-46. doi: 10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16. Ann Rheum Dis. 2015. PMID: 24344160 Free PMC article. Clinical Trial.
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT).
Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman DD, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen JS. Antoni CE, et al. Among authors: keystone e. J Rheumatol. 2008 May;35(5):869-76. Epub 2008 Mar 15. J Rheumatol. 2008. PMID: 18381786 Clinical Trial.
Cell-signaling therapy in rheumatoid arthritis.
Keystone E, Cohen MD. Keystone E, et al. Curr Rheumatol Rep. 2013 Oct;15(10):368. doi: 10.1007/s11926-013-0368-5. Curr Rheumatol Rep. 2013. PMID: 23955067 Review.
Optimizing treatment with biologics.
Mader R, Keystone E. Mader R, et al. Among authors: keystone e. J Rheumatol Suppl. 2007 Nov;80:16-24. J Rheumatol Suppl. 2007. PMID: 17985419 Review.
Self-reported comorbidity is common in early inflammatory arthritis and associated with poorer function and worse arthritis disease outcomes: results from the Canadian Early Arthritis Cohort.
Hitchon CA, Boire G, Haraoui B, Keystone E, Pope J, Jamal S, Tin D, Thorne C, Bykerk VP; CATCH investigators. Hitchon CA, et al. Among authors: keystone e. Rheumatology (Oxford). 2016 Oct;55(10):1751-62. doi: 10.1093/rheumatology/kew061. Epub 2016 Jun 21. Rheumatology (Oxford). 2016. PMID: 27330161
447 results